Drug Regulation and Oversight, from Local to Global

被引:1
作者
Babyar, Julie [1 ]
机构
[1] 415 Herondo St,Apt 332, Hermosa Beach, CA 90254 USA
关键词
Drug regulation; Regulatory medicine; Drug approval; International drug harmonization; Global medicine regulation; APPROVAL;
D O I
10.1007/s12247-017-9280-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this perspective piece is to address the potential for drug and medical product innovation through sound regulation and strengthened international harmonization. Current literature, recommendations and guidelines in regulatory agencies assisted in this perspective review. Multiple guidelines and recommendations provide for strategic planning and process improvement capabilities at local, national and international levels. Seeking best practice starts with identifying and improving individual nation drug regulatory bodies, including the US Food and Drug Administration (FDA). Inefficiency causes and process improvement solutions have been suggested and outlined in strategic plans at the FDA as well as with multiple stakeholder organizations and public-private partnerships. Cohesively, these groups should be tasked with formal, consistent updates on improvement as well as ongoing supportive research and evaluation of the changes implemented. Simultaneously, the international community has a tremendous opportunity to act on best practice for drug and medical product innovation by aligning sound and consistent approach to regulation.
引用
收藏
页码:185 / 187
页数:3
相关论文
共 50 条
  • [21] Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies
    Lexchin, Joel
    O'Donovan, Orla
    SOCIAL SCIENCE & MEDICINE, 2010, 70 (05) : 643 - 647
  • [22] Free-of-charge medicine schemes in the NHS: A local and regional drug and therapeutic committee's experience
    O'Callaghan, Simon
    Ferner, Robin E.
    Barron, Andrew
    Saxby, Katherine
    Sofat, Reecha
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (06) : 2571 - 2580
  • [24] From Concept to Regulatory Drug Approval: Lessons for Theranostics
    Perera, Marlon
    Morris, Michael J.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (12) : 1793 - 1801
  • [25] Techno-politics of genomic nationalism: Tracing genomics and its use in drug regulation in Japan and Taiwan
    Kuo, Wen-Hua
    SOCIAL SCIENCE & MEDICINE, 2011, 73 (08) : 1200 - 1207
  • [26] From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt
    Elgarhy, Fadya M.
    Borham, Abdallah
    Alziny, Noha
    AbdElaal, Khlood R.
    Shuaib, Mahmoud
    Musaibah, Abobaker Salem
    Hussein, Mohamed Ali
    Abdelnaser, Anwar
    PHARMACEUTICALS, 2024, 17 (07)
  • [27] Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan
    Kawabata-Shoda, E.
    Masuda, S.
    Kimura, H.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (05) : 547 - 552
  • [28] Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation
    Raimond, Veronique C.
    Feldman, William B.
    Rome, Benjamin N.
    Kesselheim, Aaron S.
    MILBANK QUARTERLY, 2021, 99 (01) : 240 - 272
  • [29] New science, drug regulation, and emergent public health issues: The work of FDA's division of applied regulatory science
    Chiu, Kimberly
    Racz, Rebecca
    Burkhart, Keith
    Florian, Jeffry
    Ford, Kevin
    Iveth Garcia, M.
    Geiger, Robert M. M.
    Howard, Kristina E. E.
    Hyland, Paula L. L.
    Ismaiel, Omnia A. A.
    Kruhlak, Naomi L. L.
    Li, Zhihua
    Matta, Murali K. K.
    Prentice, Kristin W. W.
    Shah, Aanchal
    Stavitskaya, Lidiya
    Volpe, Donna A. A.
    Weaver, James L. L.
    Wu, Wendy W. W.
    Rouse, Rodney
    Strauss, David G. G.
    FRONTIERS IN MEDICINE, 2023, 9
  • [30] US Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer
    Ribeiro, Tatiane Bomfim
    Ribeiro, Adalton
    Rodrigues, Luiza de Oliveira
    Harada, Guilherme
    Nobre, Moacyr Roberto Cuce
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (01) : 20 - 28